Ghoshal Kaushik's Form 4 filing
Resmed Inc (RMD) · filed Mar 4, 2025
- Accession no.
- 0001127602-25-007977
- Filed
- Mar 4, 2025
- Trade date
- Mar 3, 2025
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 8 non-derivative transactions and 4 derivative transactions. Open-market sales total $2.15M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ghoshal KaushikCIK 0001881922 | Officer (Chief Commercial Officer, SaaS) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 3, 2025 | ResMed Common Stock | MOption exerciseAcquired | +367 | $211.76 | +$77,715.92 | 10,092 | Direct | |
| Mar 3, 2025 | ResMed Common Stock | MOption exerciseAcquired | +3,506 | $146.34 | +$513,068.04 | 13,598 | Direct | |
| Mar 3, 2025 | ResMed Common Stock | MOption exerciseAcquired | +514 | $146.34 | +$75,218.76 | 14,112 | Direct | |
| Mar 3, 2025 | ResMed Common Stock | MOption exerciseAcquired | +4,726 | $211.76 | +$1,000,777.76 | 18,838 | Direct | |
| Mar 3, 2025 | ResMed Common Stock | SSaleDisposed | −367 | $235.25F2 | −$86,336.75 | 18,471 | Direct | |
| Mar 3, 2025 | ResMed Common Stock | SSaleDisposed | −3,506 | $235.40F2 | −$825,312.4 | 14,965 | Direct | |
| Mar 3, 2025 | ResMed Common Stock | SSaleDisposed | −514 | $235.25F2 | −$120,918.5 | 14,451 | Direct | |
| Mar 3, 2025 | ResMed Common Stock | SSaleDisposed | −4,726 | $235.43F2 | −$1,112,642.18 | 9,725 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 3, 2025 | ResMed Common Stock | MOption exerciseDisposed | −367 | $0.00 | $0 | 105 | Direct | |
| Mar 3, 2025 | ResMed Common Stock | MOption exerciseDisposed | −3,506 | $0.00 | $0 | 3,589 | Direct | |
| Mar 3, 2025 | ResMed Common Stock | MOption exerciseDisposed | −514 | $0.00 | $0 | 169 | Direct | |
| Mar 3, 2025 | ResMed Common Stock | MOption exerciseDisposed | −4,726 | $0.00 | $0 | 5,882 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $235.00 - $236.18. The price reported above reflects the weighted average sale price.
Referenced by the price of 4 transactions in Table I.